Humana (HUM) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- Marvell agrees to acquire Lumentum in all-stock deal valued at $115B
- Cipher Digital posts Q3 revenue of $27M, logs first HPC lease income
- Binance sees spike in withdrawals as exchange returns online after $6.3 billion heist
- Oracle files to offer $10B in common stock alongside senior notes
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Humana Reports Second Quarter 2015 Financial Results; Reaffirms 2015 Financial Guidance
July 29, 2015 7:30 AM EDT2Q 2015 EPS of $2.85 includes $1.18 of gain related to sale of Concentra 2Q 2015 Adjusted EPS of $1.67 excludes the Concentra 2Q 2015 gain and compares to managements guidance of $1.60 to $1.65 Reaffirmed full-year 2015 EPS guidance of approximately $9.28 or $7.75 on an Adjusted basis (excluding the year-to-date gain on sale of Concentra of $1.53 per share) 2Q 2015 Medicare Advantage utilization seen as stabilizing and tracking with managements revised expectations Actions taken to improve profitability of individual commercial and state-based contracts businesses
... More



